Combioxin is a clinical-stage biotechnology company dedicated to the development of first-in-class life-saving drugs for critically ill patients.
PIPELINE
Severe Infections
CAL02, a first-in-class, broad-spectrum, anti-virulence agent under development for the treatment of severe community-acquired bacterial pneumonia (SCAP).
Acquired immune deficiency
Groundbreaking approach tailored to treat acquired immune deficiency in critically ill patients by restoring immune function and immune homeostasis.
NEWS
FDA grants Qualified Infectious Disease Product (QIDP) and Fast-Track Designations for CAL02
June 13, 2023
Acceptance of Investigational New Drug application to FDA for CAL02 for the treatment of severe community-acquired bacterial pneumonia
November 11, 2022
FOUNDING TEAM
Samareh Azeredo da Silveira Lajaunias, PhD
Managing Director
Frédéric Lajaunias, PhD
Managing Director
CONTACT US
Address
Route de la Corniche 8
1066 Epalinges – Switzerland
info(a7)combioxin.com